D. Boral Capital Maintains Buy on AVITA Medical, Maintains $10 Price Target
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $10 price target.
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $10 price target.